Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 27;5(2):otad011.
doi: 10.1093/crocol/otad011. eCollection 2023 Apr.

The Winning Line Up: Positioning Advanced Therapies for Ulcerative Colitis

Erin M Forster  1
Affiliations
Editorial

The Winning Line Up: Positioning Advanced Therapies for Ulcerative Colitis

Erin M Forster. Crohns Colitis 360. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

E.M.F. holds the position of Associate Editor for Crohn’s and Colitis 360 and has been recused from reviewing or making decisions for the manuscript. Abbvie—research support, speakers bureau; BMS—research support, speakers bureau, Janssen—research support, speakers bureau; Takeda—research support.

Comment in

References

    1. Al Bawardy B, Shivasahankar R, Proctor D.. Novel and emerging therapies for inflammatory bowel disease. Front Pharmacol. 2021;12:1–16. - PMC - PubMed
    1. Sands BE, Peyrin-Biroulet L, Loftus E, et al. . Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1216–1226. - PubMed
    1. Sands BE, Irving PM, Hoops T, et al. . Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: a multicenter, randomized, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–2211. - PubMed
    1. Danese S, Colombel JF, Lukas M, et al. . Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomized, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(1):118–127. - PubMed
    1. Panaccione R, Collins EB, Melmed GY, et al. . Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohn’s Colitis 360 2023:otad009. doi:10.1093/crocol/otad009 - DOI - PMC - PubMed

Publication types

LinkOut - more resources